An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Cited by (3,231)

Items 201–300 of 3,231

1. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
   Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, Shayne F. Andrew, Barbara J. Flynn, Anne P. Werner, Danielle A. Wagner, I‐Ting Teng, Bob C. Lin, Christopher A. Moore et al. · 2022 · Cell
2. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
   Arshpreet Kaur, Jeremy Baldwin, Deshkanwar Singh Brar, Deepak B. Salunke, Nikolai Petrovsky · 2022 · Current Opinion in Chemical Biology
3. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
   Teo, Shyh Poh · 2022 · Journal of Pharmacy Practice
4. Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
   Mounzer Agha, Maggie Blake, Charles Chilleo, Alan H. Wells, Ghady Haidar · 2021 · Open Forum Infectious Diseases
5. Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System
   Pattipeiluhu, Roy, Arias‐Alpizar, Gabriela, Basha, Genc, Chan, Karen Y. T., Bussmann, Jeroen, Sharp, Thomas H., Moradi, Mohammad‐Amin, Sommerdijk, Nico, Harris, Edward N., Cullis, Pieter R. et al. · 2022 · Advanced Materials
6. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice
   de Alwis, Ruklanthi, Gan, Esther S., Chen, Shiwei, Leong, Yan Shan, Tan, Hwee Cheng, Zhang, Summer L., Yau, Clement, Low, Jenny G.H., Kalimuddin, Shirin, Matsuda, Daiki et al. · 2021 · Molecular Therapy
7. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
   Beaudoin-Bussières, Guillaume, Laumaea, Annemarie, Anand, Sai Priya, Prévost, Jérémie, Gasser, Romain, Goyette, Guillaume, Medjahed, Halima, Perreault, Josée, Tremblay, Tony, Lewin, Antoine et al. · 2020 · mBio
8. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
   David R. Martinez, Alexandra Schäfer, Sarah R. Leist, Gabriela De la Cruz, Ande West, Elena N. Atochina‐Vasserman, Lisa C. Lindesmith, Norbert Pardi, Robert Parks, Maggie Barr et al. · 2021 · Science
9. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
   2021
10. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
    Renuka Raman, Krishna J. Patel, Kishu Ranjan · 2021 · Biomolecules
11. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
    Rebecca Grainger, Alfred H.J. Kim, Richard P. Conway, Jinoos Yazdany, Philip Cameron Robinson · 2022 · Nature Reviews Rheumatology
12. Structural basis for broad coronavirus neutralization
    Maximilian M. Sauer, M. Alejandra Tortorici, Young‐Jun Park, Alexandra C. Walls, Leah J. Homad, Oliver J. Acton, John E. Bowen, Chunyan Wang, Xiaoli Xiong, Willem de van der Schueren et al. · 2021 · Nature Structural & Molecular Biology
13. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
    Colin Pawlowski, Patrick J. Lenehan, Arjun Puranik, Vineet Agarwal, AJ Venkatakrishnan, Michiel J.M. Niesen, John Charles O’Horo, Abinash Virk, Melanie D. Swift, Andrew D. Badley et al. · 2021 · Med
14. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
    Walls, Alexandra C., Miranda, Marcos C., Schäfer, Alexandra, Pham, Minh N., Greaney, Allison, Arunachalam, Prabhu S., Navarro, Mary-Jane, Tortorici, M. Alejandra, Rogers, Kenneth, O’Connor, Megan A. et al. · 2021 · Cell
15. Vaccine delivery systems toward lymph nodes
    Yingyue Ding, Zhaoting Li, Ana Jaklenec, Quanyin Hu · 2021 · Advanced Drug Delivery Reviews
16. T Cell Responses to SARS-CoV-2
    Alessandro Sette, John Sidney, Shane Crotty · 2023 · Annual Review of Immunology
17. Polymer‐Based mRNA Delivery Strategies for Advanced Therapies
    Wenqian Yang, Lucas Mixich, Eger Boonstra, Horacio Cabral · 2023 · Advanced Healthcare Materials
18. Nanotechnology for modern medicine: next step towards clinical translation
    Shrey Sindhwani, Warren C. W. Chan · 2021 · Journal of Internal Medicine
19. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
    Laura Pérez‐Alós, José Juan Almagro Armenteros, Johannes Roth Madsen, Cecilie Bo Hansen, Ida Jarlhelt, Sebastian Rask Hamm, Line Dam Heftdal, Mia Marie Pries‐Heje, Dina Leth Møller, Kamille Fogh et al. · 2022 · Nature Communications
20. Drug combination therapy for emerging viral diseases
    Zeenat A. Shyr, Yu‐Shan Cheng, Donald C. Lo, Wei Zheng · 2021 · Drug Discovery Today
21. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
    2022
22. Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly
    Branca Isabel Pereira, Xiao‐Ning Xu, Arne N. Akbar · 2020 · Frontiers in Immunology
23. Human IgG and IgA responses to COVID-19 mRNA vaccines
    Julian Campillo Luna, Adam V. Wisnewski, Carrie A. Redlich · 2021 · PLoS ONE
24. Nanovaccines: A game changing approach in the fight against infectious diseases
    Priyanka, Mai Abdel Haleem Abusalah, Hitesh Chopra, Abhilasha Sharma, Suhad Asad Mustafa, Om Prakash Choudhary, Manish Kumar Sharma, Manish K. Dhawan, Rajiv Khosla, Aanchal Loshali et al. · 2023 · Biomedicine & Pharmacotherapy
25. Nucleic acid drugs: recent progress and future perspectives
    Xiaoyi Sun, Sarra Setrerrahmane, Chencheng Li, Jialiang Hu, Hanmei Xu · 2024 · Signal Transduction and Targeted Therapy
26. Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells
    Margaret M. Billingsley, Alex G. Hamilton, David Mai, Savan K. Patel, Kelsey L. Swingle, Neil C. Sheppard, Carl H. June, Michael J. Mitchell · 2021 · Nano Letters
27. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
    Vanshylla, Kanika, Di Cristanziano, Veronica, Kleipass, Franziska, Dewald, Felix, Schommers, Philipp, Gieselmann, Lutz, Gruell, Henning, Schlotz, Maike, Ercanoglu, Meryem S., Stumpf, Ricarda et al. · 2021 · Cell Host & Microbe
28. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
    Chris R. Triggle, Devendra Bansal, Hong Ding, Md. Mazharul Islam, Elmoubasher Farag, Hamad Abdel Hadi, Ali A. Sultan · 2021 · Frontiers in Immunology
29. Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies
    Jonah Clegg, Elisabetta Soldaini, Rachel M. McLoughlin, Stephen F. Rittenhouse, Fábio Bagnoli, Sanjay Kumar Phogat · 2021 · Frontiers in Immunology
30. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients
    Dominique Bertrand, M. Hamzaoui, Véronique Lemee, Julie Lamulle, Mélanie Hanoy, Charlotte Laurent, Ludivine Lebourg, Isabelle Étienne, Mathilde Lemoine, Frank Le Roy et al. · 2021 · Journal of the American Society of Nephrology
31. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63
    Woldemeskel, Bezawit A., Garliss, Caroline C., Blankson, Joel N. · 2021 · Journal of Clinical Investigation
32. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness
    Ruian Ke, Carolin Zitzmann, David D. Ho, Ruy Miguel Ribeiro, Alan S. Perelson · 2021 · Proceedings of the National Academy of Sciences
33. Non-liver mRNA Delivery
    Loughrey, David, Dahlman, James E. · 2022 · Accounts of Chemical Research
34. Learning from the past: development of safe and effective COVID-19 vaccines
    Shan Su, Lanying Du, Shibo Jiang · 2020 · Nature Reviews Microbiology
35. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies
    Miquéias Lopes‐Pacheco, Pedro Leme Silva, Fernanda Ferreira Cruz, Denise Battaglini, Chiara Robba, Paolo P. Pelosi, Marcelo Marcos Morales, Celso Caruso Neves, Patrícia R. M. Rocco · 2021 · Frontiers in Physiology
36. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
    Edara, Venkata Viswanadh, Hudson, William H., Xie, Xuping, Ahmed, Rafi, Suthar, Mehul S. · 2021 · JAMA
37. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
    Scheaffer, Suzanne M., Lee, Diana, Whitener, Bradley, Ying, Baoling, Wu, Kai, Liang, Chieh-Yu, Jani, Hardik, Martin, Philippa, Amato, Nicholas J., Avena, Laura E. et al. · 2023 · Nature Medicine
38. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
    Wafaa B. Alsoussi, Sameer Kumar Malladi, Julian Q. Zhou, Zhuoming Liu, Baoling Ying, Wooseob Kim, Aaron J. Schmitz, Tingting Lei, Stephen C. Horvath, Alexandria J. Sturtz et al. · 2023 · Nature
39. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
    Alexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, Shang Yu Gong, Romain Gasser, Guillaume Beaudoin-Bussières, Nathalie Brassard, Annemarie Laumaea, Dani Vézina, Jérémie Prévost et al. · 2021 · Cell Host & Microbe
40. Immunity to SARS‐CoV‐2 induced by infection or vaccination
    Xaquín Castro Dopico, Sebastian Ols, Karin Loré, Gunilla B. Karlsson Hedestam · 2021 · Journal of Internal Medicine
41. The known unknowns of T cell immunity to COVID-19
    Karlsson, Annika C., Humbert, Marion, Buggert, Marcus · 2020 · Science Immunology
42. Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm
    Wei Wang, Shuo Feng, Zhuyifan Ye, Hanlu Gao, Jinzhong Lin, Defang Ouyang · 2021 · Acta Pharmaceutica Sinica B
43. mRNA cancer vaccines: Advances, trends and challenges
    Qing He, Hua Gao, Dejiang Tan, Heng Zhang, Junzhi Wang · 2022 · Acta Pharmaceutica Sinica B
44. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration
    Ruirong Chen, Zhien Lan, Jujian Ye, Limin Pang, Yi Liu, Wei Wu, Xiaohuan Qin, Yang Guo, Peidong Zhang · 2021 · Frontiers in Immunology
45. Shedding of infectious SARS-CoV-2 despite vaccination
    Kasen K. Riemersma, Luis A. Haddock, Nancy A. Wilson, Nicholas R. Minor, Jens C. Eickhoff, Brittany Grogan, Amanda Kita-Yarbro, Peter Halfmann, Hannah E. Segaloff, Anna Kocharian et al. · 2022 · PLoS Pathogens
46. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study
    Steven Mark Rowe, Jonathan B. Zuckerman, Daniel J. Dorgan, Jorge E. Lascano, Karen McCoy, Manu Jain, Michael S. Schechter, Sherstin T. Lommatzsch, V. Indihar, Noah Lechtzin et al. · 2023 · Journal of Cystic Fibrosis
47. Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand
    Zoltán Kis, Cleo Kontoravdi, Robin J. Shattock, Nilay Shah · 2020 · Vaccines
48. Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19
    Rajesh Kumar Thimmulappa, Kiran Kumar Mudnakudu-Nagaraju, Chandan Shivamallu, Kuttinchantran Subramaniam, Arun Radhakrishnan, Suresh Bhojraj, Gowthamarajan Kuppusamy · 2021 · Heliyon
49. Air−Liquid Interface Cultures of the Healthy and Diseased Human Respiratory Tract: Promises, Challenges, and Future Directions
    Domizia Baldassi, Bettina Gabold, Olivia M. Merkel · 2021 · Advanced NanoBiomed Research
50. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects
    Jingan Chen, Yue Xu, Muye Zhou, Shufen Xu, Andrew Varley, Alex Golubovic, Rick Xing Ze Lu, Kevin Chang Wang, M Yeganeh, Daniel Vosoughi et al. · 2023 · Proceedings of the National Academy of Sciences
51. Synthesis and Potential Applications of Lipid Nanoparticles in Medicine
    Ewelina Musielak, Agnieszka Feliczak‐Guzik, Izabela Nowak · 2022 · Materials
52. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
    Tatjana Bilich, Annika Nelde, Jonas S. Heitmann, Yacine Maringer, Malte Roerden, Jens Bauer, Jonas Rieth, Marcel Wacker, Andreas Peter, Sebastian Hörber et al. · 2021 · Science Translational Medicine
53. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects
    Sarah Wheeler, Galina V. Shurin, Mary Yost, Adam Anderson, Lisa Pinto, Alan H. Wells, Michael R. Shurin · 2021 · Microbiology Spectrum
54. The Past, Present, and Future of Non-Viral CAR T Cells
    Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara Francesca Magnani · 2022 · Frontiers in Immunology
55. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
    Oren K. Fix, Emily A. Blumberg, Kyong‐Mi Chang, Jaime Chu, Raymond T. Chung, Elizabeth K. Goacher, Bilal Hameed, Daniel R. Kaul, Laura Kulik, Ryan M. Kwok et al. · 2021 · Hepatology
56. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
    Qian He, Qunying Mao, Chaoqiang An, Jialu Zhang, Fan Gao, Lianlian Bian, Changgui Li, Zhenglun Liang, Miao Xu, Junzhi Wang · 2021 · Emerging Microbes & Infections
57. Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
    Cagigi, Alberto, Loré, Karin · 2021 · Vaccines
58. COVID-19 and cellular senescence
    Schmitt, Clemens A., Tchkonia, Tamar, Niedernhofer, Laura J., Robbins, Paul D., Kirkland, James L., Lee, Soyoung · 2023 · Nature Reviews Immunology
59. Immune responses during COVID-19 infection
    Cléa Melenotte, Aymeric Silvin, Anne‐Gaëlle Goubet, Imran Lahmar, Agathe Dubuisson, Alimuddin I. Zumla, Didier Raoult, Mansouria Merad-Boudia, Bertrand Gachot, Clémence Henon et al. · 2020 · OncoImmunology
60. The transmission modes and sources of COVID-19: A systematic review
    Heshu Sulaiman Rahman, Masrur S. Aziz, Ridha Hassan Hussein, Hemn Hassan Othman, Shirwan Hama Salih Omer, Eman Star Khalid, Nusayba Abdulrazaq Abdulrahman, Kawa Amin, Rasedee Abdullah · 2020 · International Journal of Surgery Open
61. Revealing Public Opinion Towards COVID-19 Vaccines With Twitter Data in the United States: Spatiotemporal Perspective
    Tao Hu, Siqin Wang, Wei Ping Luo, Mengxi Zhang, Xiao Huang, Yingwei Yan, Regina Liu, Kelly Ly, Viraj Kacker, Bing She et al. · 2021 · Journal of Medical Internet Research
62. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
    Chava Perry, Efrat Luttwak, Roi Balaban, Gabi Shefer, M. Morales, Adi Aharon, Yaara Tabib, Yael Chava Cohen, Noam Benyamini, Ofrat Beyar‐Katz et al. · 2021 · Blood Advances
63. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients
    Victoria G. Hall, Victor H. Ferreira, Matthew Ierullo, Terrance Ku, Tina M. Marinelli, Beata Majchrzak-Kita, Anila Yousuf, Vathany Kulasingam, Atul Humar, Deepali Kumar · 2021 · American Journal of Transplantation
64. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
    Sindhu Ramesh, Manoj Govindarajulu, Rachel S. Parise, Logan T. Neel, Tharanath Shankar, Shriya Patel, Payton Lowery, Forrest Smith, Muralikrishnan Dhanasekaran, Timothy Moore · 2021 · Vaccines
65. Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
    David S. Khoury, Timothy E. Schlub, Deborah Cromer, Megan C. Steain, Youyi Fong, Peter B. Gilbert, Kanta Subbarao, James A. Triccas, Stephen John Kent, Miles P. Davenport · 2023 · Emerging infectious diseases
66. Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation
    Bahaa Jawad, Puja Adhikari, Rudolf Podgornik, W. Y. Ching · 2021 · Journal of Chemical Information and Modeling
67. Can a COVID-19 vaccine live up to Americans’ expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions
    Matt Motta · 2021 · Social Science & Medicine
68. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
    Kimberly Risma, Kathryn M. Edwards, Donna S. Hummell, Frédéric F. Little, Allison Eaddy Norton, Amy Polen Stallings, Robert A. Wood, Joshua D. Milner · 2021 · Journal of Allergy and Clinical Immunology
69. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
    Bogdan Doroftei, Alin Stelian Ciobica, Ovidiu‐Dumitru Ilie, Radu Maftei, Ciprian Gavrilă Ilea · 2021 · Diagnostics
70. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
    Pan-Pan Zhou, Ge Song, Hejun Liu, Meng Yuan, Wanting He, Nathan Beutler, Xueyong Zhu, Longping V. Tse, David R. Martinez, Alexandra Schäfer et al. · 2023 · Immunity
71. Trends and Innovations of Simulation for Twenty First Century Medical Education
    Herrera-Aliaga, Eduardo, Estrada, Lisbell D. · 2022 · Frontiers in Public Health
72. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
    Aliprantis, Antonios O., Shaw, Christine A., Griffin, Paul, Farinola, Nicholas, Railkar, Radha A., Cao, Xin, Liu, Wen, Sachs, Jeffrey R., Swenson, Christine J., Lee, Heather et al. · 2021 · Human Vaccines & Immunotherapeutics
73. The Covid-19 Vaccine-Development Multiverse
    Penny M. Heaton · 2020 · New England Journal of Medicine
74. “COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment”
    Girish Gilly Munavalli, Rachel Guthridge, Siri Knutsen-Larson, Amy Brodsky, Ethan J Matthew, Marina Landau · 2021 · Archives of Dermatological Research
75. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
    Weingarten-Gabbay, Shira, Klaeger, Susan, Sarkizova, Siranush, Pearlman, Leah R., Chen, Da-Yuan, Gallagher, Kathleen M.E., Bauer, Matthew R., Taylor, Hannah B., Dunn, W. Augustine, Tarr, Christina et al. · 2021 · Cell
76. Antibody-mediated neutralization of SARS-CoV-2
    Henning Gruell, Kanika Vanshylla, Timm Weber, Christopher O. Barnes, Christoph Kreer, Florian Klein · 2022 · Immunity
77. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development
    Subodh Kumar Samrat, Anil Mathew Tharappel, Zhong Li, Hongmin Li · 2020 · Virus Research
78. Current Prevention of COVID-19: Natural Products and Herbal Medicine
    Junqing Huang, Gabriel Tao, Jingwen Liu, Junming Cai, Zhongyu Huang, Jiaxu Chen · 2020 · Frontiers in Pharmacology
79. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
    Scott Wesley Long, Randall J. Olsen, Paul A. Christensen, David W. Bernard, James J. Davis, Maulik P. Shukla, Marcus Nguyen, Matthew Ojeda Saavedra, Prasanti Yerramilli, Layne Pruitt et al. · 2020 · mBio
80. Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
    Iliès Benotmane, Gabriela Gautier-Vargas, Noëlle Cognard et al. · 2021 · Kidney International
81. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines
    Yannic C. Bartsch, Xin Tong, Jaewon Kang, María José Avendaño, Eileen F. Serrano, Tamara García‐Salum, Catalina Pardo‐Roa, Arnoldo J. Riquelme, Yongfei Cai, Isabella Renzi et al. · 2022 · Science Translational Medicine
82. Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins
    Yong Zhang, Wanjun Zhao, Yonghong Mao, Yaohui Chen, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Dan Du, Xiaofeng Lu et al. · 2020 · Molecular & Cellular Proteomics
83. From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants
    VASILEIOS S. PAPANIKOLAOU, Aristeidis Chrysovergis, Vasileios Ragos, Evangelos Tsiambas, Spyros Katsinis, Arezina Manoli, Sotirios M. Papouliakos, Dimitrios Roukas, Stylianos N. Mastronikolis, Dimitrios Peschos et al. · 2022 · Gene
84. Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
    Swingle, Kelsey L., Safford, Hannah C., Geisler, Hannah C., Hamilton, Alex G., Thatte, Ajay S., Billingsley, Margaret M., Joseph, Ryann A., Mrksich, Kaitlin, Padilla, Marshall S., Ghalsasi, Aditi A. et al. · 2023 · Journal of the American Chemical Society
85. COVID‐19 vaccinations: The unknowns, challenges, and hopes
    Kawthar Mohamed, Piotr Rzymski, Md Shahidul Islam, Rangarirai Makuku, Ayesha Mushtaq, Amjad Khan, Mariya Ivanovska, Sara A. Makka, Fareeda Hashem, Leander Penaso Marquez et al. · 2021 · Journal of Medical Virology
86. The use of RNA-based treatments in the field of cancer immunotherapy
    Mohammad Chehelgerdi, Matin Chehelgerdi · 2023 · Molecular Cancer
87. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
    Fengcai Zhu, Chunlan Zhuang, Kai Chu, Liang Zhang, Hui John Zhao, Shoujie Huang, Yingying Su, Hong‐Yan Lin, Changlin Yang, Han-Min Jiang et al. · 2022 · The Lancet Respiratory Medicine
88. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
    Tsai, Shang Jui, Atai, Nadia A., Cacciottolo, Mafalda, Nice, Justin, Salehi, Arjang, Guo, Chenxu, Sedgwick, Alanna, Kanagavelu, Saravana, Gould, Stephen J. · 2021 · Journal of Biological Chemistry
89. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
    Vogel, Annette B., Kanevsky, Isis, Che, Ye, Swanson, Kena A., Muik, Alexander, Vormehr, Mathias, Kranz, Lena M., Walzer, Kerstin C., Hein, Stephanie, Güler, Alptekin et al. · 2020
90. Omics-Driven Biotechnology for Industrial Applications
    Bashar Amer, Edward E. K. Baidoo · 2021 · Frontiers in Bioengineering and Biotechnology
91. Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality
    Mehul D. Patel, Erik Rosenstrom, Julie Simmons Ivy, María E. Mayorga, Pınar Keskinocak, Ross M. Boyce, Kristen Hassmiller Lich, Raymond Smith, Karl Johnson, Paul L. Delamater et al. · 2021 · JAMA Network Open
92. mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
    Andaleeb Sajid, Jaqueline Matias, Gunjan Arora, Cheyne Kurokawa, Kathleen DePonte, Xiao‐Tian Tang, Geoffrey E. Lynn, Ming-Jie Wu, Utpal Pal, Norma Olivares Strank et al. · 2021 · Science Translational Medicine
93. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
    Yi-Zhou Jiang, Limor Rubin, Tangming Peng, Linlin Liu, Xingan Xing, Philip Lazarovici, Wenhua Zheng · 2021 · International Journal of Biological Sciences
94. Therapeutic induction of antigen-specific immune tolerance
    Jessica E. Kenison, Nikolas A. Stevens, Francisco Javier Quintana · 2023 · Nature reviews. Immunology
95. Neutralising antibodies predict protection from severe COVID-19
    Cromer, Deborah, Steain, Megan, Reynaldi, Arnold, Schlub, Timothy E, Sasson, Sarah C, Kent, Stephen J, Khoury, David S, Davenport, Miles Philip · 2022
96. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization
    Michele A. Kohli, Michael Maschio, Debbie L. Becker, Milton C. Weinstein · 2021 · Vaccine
97. SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment
    Dapeng Li, Gregory D. Sempowski, Kevin O. Saunders, Priyamvada Acharya, Barton F. Haynes · 2021 · Annual Review of Medicine
98. Efforts at COVID-19 Vaccine Development: Challenges and Successes
    Azizul Haque, Anudeep B. Pant · 2020 · Vaccines
99. Consideration for the scale‐up manufacture of nanotherapeutics—A critical step for technology transfer
    Xiangsheng Liu, Huan Meng · 2021 · Open Research (University of Surrey)
100. Nanomaterials for Therapeutic RNA Delivery
     Xuexiang Han, Michael J. Mitchell, Guangjun Nie · 2020 · Matter